Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms

Ayalew Tefferi; Ross L. Levine; Hagop Kantarjian

doi:10.1016/j.bbmt.2008.10.010

Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms

Ayalew Tefferi, Ross L. Levine, Hagop Kantarjian

Hematology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

Original language	English (US)
Pages (from-to)	114-119
Number of pages	6
Journal	Biology of Blood and Marrow Transplantation
Volume	15
Issue number	1 SUPPL.
DOIs	https://doi.org/10.1016/j.bbmt.2008.10.010
State	Published - Jan 2009

Keywords

Polycythemia
leukemia
mutation
myelofibrosis
thrombocythemia

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2008.10.010

Cite this

@article{6f69cdeb364b49fba4f2b50d21160870,

title = "Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms",

abstract = "Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.",

keywords = "Polycythemia, leukemia, mutation, myelofibrosis, thrombocythemia",

author = "Ayalew Tefferi and Levine, {Ross L.} and Hagop Kantarjian",

year = "2009",

month = jan,

doi = "10.1016/j.bbmt.2008.10.010",

language = "English (US)",

volume = "15",

pages = "114--119",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "1 SUPPL.",

}

TY - JOUR

T1 - Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms

AU - Tefferi, Ayalew

AU - Levine, Ross L.

AU - Kantarjian, Hagop

PY - 2009/1

Y1 - 2009/1

N2 - Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

AB - Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

KW - Polycythemia

KW - leukemia

KW - mutation

KW - myelofibrosis

KW - thrombocythemia

UR - http://www.scopus.com/inward/record.url?scp=64749115365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749115365&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.10.010

DO - 10.1016/j.bbmt.2008.10.010

M3 - Article

C2 - 19147089

AN - SCOPUS:64749115365

SN - 1083-8791

VL - 15

SP - 114

EP - 119

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 1 SUPPL.

ER -

Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this